Hosted content
GPnotebook hosts a limited amount of content on behalf of third parties. Such content includes microsites (discrete mini-websites) available via the links below. Microsite content is developed by, and is the responsibility of, the sponsoring company. GPnotebook has had no input into the content. To enquire about hosting a microsite resource, please contact us.
Residual CV risk beyond LDL-C: A practical approach for general practicePromotional content from CSL Seqirus for healthcare professionals in Australia only
Explore Vazkepa® (icosapent ethyl), TGA-indicated to reduce cardiovascular risk in statin‑treated adults with triglycerides ≥1.7–5.6 mmol/L and established cardiovascular disease, or diabetes plus ≥1 additional cardiovascular risk factor.
AU-VZKP-26-0060 | July 2026
Please review Product Information before prescribing. Product Information available at www.tga.gov.au/resources/auspmd/vazkepa or www.cslseqirus.com.au/products.
Understanding the mRNA Technology PlatformThe content of this website is intended for Australian healthcare professionals only. All content has been funded and developed by Moderna Australia Pty Ltd.
Learn from global experts as they explore how mRNA technology works and how it can help protect patients from infectious diseases.
AU-NP-MPS-2500001 | January 2026